Nobiletin Prevents D-Galactose-Induced C2C12 Cell Aging by Improving Mitochondrial Function

Area of Science:

• Gerontology and Muscle Physiology
• Molecular Biology and Aging
• Pharmacology and Natural Compounds

Background:

• Age-related skeletal muscle loss (sarcopenia) significantly impairs mobility and independence in the elderly.
• Understanding the molecular mechanisms underlying sarcopenia is crucial for developing effective interventions.
• C2C12 myoblast aging models provide valuable insights into cellular processes of muscle aging.

Purpose of the Study:

• To investigate the potential of nobiletin (Nob) in mitigating age-associated skeletal muscle decline.
• To elucidate the underlying molecular mechanisms by which nobiletin exerts its anti-aging effects on muscle cells.
• To assess nobiletin's impact on mitochondrial function, oxidative stress, inflammation, and apoptosis in an aging muscle model.

Main Methods:

• Utilized a D-galactose-induced C2C12 myoblast aging model to simulate age-related muscle deterioration.
• Administered nobiletin (Nob) to aged myoblasts to evaluate its therapeutic effects.
• Assessed key cellular markers including mitochondrial function, ATP production, reactive oxygen species (ROS) levels, inflammatory markers, and apoptosis.

Main Results:

• Nobiletin intervention significantly improved mitochondrial function and increased ATP production in aged myoblasts.
• Nob treatment reduced reactive oxygen species (ROS) generation, suppressed inflammation, and inhibited apoptosis.
• Enhanced autophagy function was observed, leading to the clearance of misfolded proteins and damaged organelles, thereby reducing mitochondrial damage and skeletal muscle atrophy.

Conclusions:

• Nobiletin demonstrates a multifaceted protective effect against skeletal muscle aging by simultaneously enhancing mitochondrial and autophagy functions.
• The study suggests nobiletin's potential to counteract age-related muscle atrophy through improved cellular quality control and energy metabolism.
• Nobiletin emerges as a promising therapeutic candidate for preventing and treating age-related muscle decline and sarcopenia.